|
KMID : 1022820180090020021
|
|
Journal of Multiple Sclerosis and Neuroimmunology
2018 Volume.9 No. 2 p.21 ~ p.23
|
|
|
Effectiveness of First-line Natalizumab Treatment in Patients with Highly Active Relapsing-remitting Multiple Sclerosis
|
|
Kim Su-Hyun
Kim Ho-Jin
|
|
|
Abstract
|
|
|
|
Patients with highly active relapsing-remitting multiple sclerosis (RRMS) may benefit from early aggressive therapy instead of the escalation approach. Here we describe the outcome of a patient with highly active RRMS (two relapses in the year after onset and a few gadolinium-enhancing lesions on brain MRI) treated with natalizumab as a first-line treatment. Over 2 years of natalizumab treatment, no evidence of disease activity was observed. An early aggressive approach may improve treatment outcome in patients with highly active RRMS.
|
|
|
KEYWORD
|
|
|
Multiple sclerosis, Natalizumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|